Ocera Therapeutics fka OCRX

[monkeyfrog]

http://www.econotimes.com/Ocera-Therapeutics-Announces-Publication-of-Promising-Preclinical-Data-in-Support-of-Its-Ammonia-Scavenger-OCR-002-in-the-Journal-of-Hepatology-192613

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 11, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the publication of promising preclinical data related to the Company’s investigational drug candidate ornithine phenylacetate, OCR-002. The paper, entitled “Ammonia produces pathological changes in human hepatic stellate cells and is a target for therapy of portal hypertension” is published in the April 2016 issue of the Journal of Hepatology (http://www.journal-of-hepatology.eu/article/S0168-8278(15)00777-1/abstract).


In this investigator-sponsored preclinical study, the authors investigated the role of ammonia in modulating human hepatic stellate cell (hHSC) activation in vitro and in vivo, and the ability of OCR-002 to lower ammonia and thus reduce resultant portal hypertension in bile duct ligated (BDL) rats, a model of cirrhosis. Portal hypertension, a complication of cirrhosis, is an increase in the blood pressure within a system of veins called the portal venous system.

Researchers subjected hHSCs to an ammonia challenge and results showed that pathophysiologic ammonia concentrations in vitro induced significant alterations in cellular morphology and caused significant and reversible changes in cell proliferation, metabolic activity, pro-inflammatory gene expression and activation markers. During the in vivo phase of the study, ammonia levels and portal pressure were compared in BDL rats vs. sham-operated controls prior to and after 5 days of treatment with OCR-002. Ammonia concentrations were significantly elevated in plasma in BDL rats compared to sham-operated rats (182 vs. 62.5µM, P < .0001), which decreased significantly following treatment with OCR-002 (83.8µM, P < .0001). These significant changes in plasma ammonia were correlated with alterations in portal pressure, which were significantly higher in BDL rats compared to sham (14 vs. 5.5mmHg, P < .0001). Ammonia lowering following administration of OCR-002 resulted in a significant reduction in portal pressure compared to BDL saline-treated rats (11mmHg, P < .01).

“The data clearly showed that increasing concentrations of ammonia were associated with marked structural and functional changes of hHSCs and that these effects were reversible when ammonia was removed from the medium and cells were allowed to recover,” said lead author Professor Rajiv Jalan, M.B.B.S, M.D. Ph.D., from the University College London. “Further, the reduction in ammonia concentration using OCR-002 resulted in a downregulation of HSCs activation markers that coincided with a significant reduction in portal pressure, providing a potential novel strategy to treat portal hypertension.”

“We are very encouraged by the study’s further findings supporting the ammonia-lowering properties of OCR-002 and its potential as a new therapy for hyperammonemic-implicated indications where current treatments are limited and or lack efficacy,” said Stan Bukofzer, M.D., Ocera’s Chief Medical Officer. “While Ocera remains focused on developing OCR-002 to potentially treat hepatic encephalopathy in patients with liver cirrhosis and acute liver failure, we believe that portal hypertension may, in the future, provide an additional clinical development opportunity for OCR-002 based on these early results.”

About Portal Hypertension

Portal hypertension, a complication of liver cirrhosis, is an increase in the blood pressure within a system of veins called the portal venous system. Veins coming from the stomach, intestine, spleen, and pancreas merge into the portal vein, which then branches into smaller vessels and travels through the liver. If the vessels in the liver are blocked due to liver damage, blood cannot flow properly through the liver. As a result, high pressure in the portal system develops. This increased pressure in the portal vein may lead to the development of large, swollen veins (varices) within the esophagus, stomach, rectum, or umbilical area (belly button). Varices can rupture and bleed, resulting in potentially life-threatening complications.

About Hepatic Encephalopathy

Hepatic encephalopathy is a debilitating and progressive complication of liver cirrhosis or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation, and in its more severe form, stupor, coma and even death.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure and acute-on-chronic liver disease.

Ocera's HE clinical development efforts include an ongoing Phase 2b clinical trial, STOP-HE, which is evaluating the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia, and a Phase 1 program evaluating the safety, tolerability and pharmacokinetics of orally-available OCR-002 for the prevention of HE. The Company expects to complete enrollment in the STOP-HE trial in the fourth quarter of 2016 with top-line data to be published soon thereafter. An additional Phase 1 study of oral OCR-002 will commence later this year after further formulation optimization. For additional information, please see www.ocerainc.com.

Forward-Looking Statements

This press release contains "forward-looking" statements, including, without limitation, all statements related to the OCR-002 clinical development program, including but not limited to the potential benefits of OCR-002 to help patients with hepatic encephalopathy, the potential benefits of OCR-002 to help patients with portal hypertension, the timing of clinical and enrollment milestones, and the timing of study data. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "expected," "hope," "plan," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ocera's current expectations. Forward-looking statements involve risks and uncertainties and Ocera's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including those risks and uncertainties discussed under the heading "Risk Factors" in Ocera's Annual Report on Form 10-K for the year ended December 31, 2015 and subsequent filings with the SEC. All information in this press release is as of the date of the release, and Ocera undertakes no duty to update this information unless required by law.

OCRX-G

Susan Sharpe
Ocera Therapeutics, Inc.
[e-mail]
919-328-1109



Primary Logo




TO GET STORIES IN REAL-TIME, SUBSCRIBE OR SIGN IN
Subscribe Now
© EconoTimes 2015. All rights reserved. The EconoTimes content received through this service is the intellectual property of EconoTimes or its third party suppliers. Republication or redistribution of content provided by EconoTimes is expressly prohibited without the prior written consent of EconoTimes, except for personal and non-commercial use. Neither EconoTimes nor its third party suppliers shall be liable for any errors, omissions or delays in content, or for any actions taken in reliance thereon.

?
?
?
?
?
?























































































































Upcoming Economic Calendar Monday, Apr 11


GMT

Time left

Event

Period

Actual

Forecast

Previous












13:00 Released MX Industrial Output YY Feb 2.6 % 1.35 % 1.10 %
13:00 Released MX Industrial Output MM Feb -0.1 % -0.35 % 1.20 %
21:00 7h 51m KR Export Price Growth YY* Mar -2 %
21:00 7h 51m KR Import Price Growth YY* Mar -7.4 %
23:01 9h 52m GB BRC Retail Sales YY Mar 0.1 %
23:50 10h 41m JP Bank Lending YY Mar 2.2 %
01:30 12h 21m AU NAB Business Conditions Mar 8
01:30 12h 21m AU NAB Business Confidence Mar 3
06:00 16h 51m DE HICP Final MM Mar 0.8 % 0.8 %
06:00 16h 51m DE HICP Final YY Mar 0.1 % 0.1 %








Economy
U.S. employers taking action to keep health care cost increases to just 4% in 2016
Guide to today’s important data and events
Fitch: Indonesia Rate Cut Not Likely To Boost Lending Soon
BRITISH GOVERNMENT SAYS LOCATION DECISION FOR NEW AIRPORT RUNWAY SUBJECT TO FURTHER CONSIDERATION ON ENVIRONMENTAL IMPACTS - STATEMENT
Fitch: India Discom Reform Success is Key to Power Sector Woes


Central Banks
BOJ LIKELY TO DEBATE POSSIBILITY OF EASING MONETARY POLICY AT APRIL 27-28 RATE REVIEW – SOURCES
BOJ offers dollar supply operation for 3/31 - 4/7 (EST)
BOJ offers to buy 600 bln yen in commercial paper (CP) from 3/31
BOJ OFFERS TO BUY 450 BLN YEN JGBS (RESIDUAL MATURITY OF 5YR TO 10YR) OUTRIGHT FROM 3/30
RBI’s easing optimism likely to affect Indian bond yields


Commentaries
German HICP inflation to remain in negative territory in coming months, sharp recovery seen in H2
Currency snapshot (commodity pairs)
US import prices likely gained in March
Brazil’s retail sales likely rebounded a bit in Feb, but points downside risk to consumption growth in Q1
Worrisome Signs Series: ‘GDP Now’ points U.S. economy at brink of recession


Research
FxWirePro: EUR/GBP IVs favour option writers, best bids in bullish neutral risk reversals for credit combos for speculation
FxWirePro: AUD/USD option sensitivity table indicates IVs conducive for OTM strikes
Moody's: Germany's economic growth to slightly accelerate in 2016, fiscal outlook remains strong
FxWirePro: EUR/USD hedging and speculating sides as per OTC adjustments
Fitch: China Hard Landing Unlikely But Reform Skepticism Rising


Insights
Hungary's benchmark rate to drop to 0.75% before year-end
FxWirePro: No signs of AUD recovery in 2016 amid significant geopolitical events
Cruz sweeps all 34 Colorado delegates, making contested Republican convention more likely
Robots can help young patients engage in rehab
To embrace our future as an innovation nation, we'll need to learn from the past


Roundups
Europe Roundup: Dollar breaches 108 level against the yen, Gold rises 3-weeks high; European shares rebound - Monday, April 11th, 2016
Asia Roundup: Yen hits fresh 18 –month high against US dollar while China’s CPI remains steady at 19- month high in March, Gold hovers around $1250 - Monday, April 11th, 2016
Americas Roundup: Dollar gains on Yen as Japanese finance minister warns on intervention, oil prices jump 6 pct on U.S. stockpile drawdowns-April 9th,2016
Europe Roundup: Sterling reverses gains on downbeat industrial data, European shares on track for 4th weekly losses - Friday, April 8th, 2016
Asia Roundup: Antipodeans head for weekly losses, Dollar steady after hitting 17-month low vs yen, Asian shares extend losses- Friday, April 8th, 2016


Digital Currencies
Cryptocurrency Wallet Service CoinWallet Announces Closure Following Data Breach
Intel Announces Highly Modular Distributed Ledger Platform ‘Sawtooth Lake’
Big Banks To Attend European Blockchain Congress On April 27
Chain, Mitsubishi UFJ Partner To Build Blockchain Solutions For Japan’s Financial Sector
Russian Central Bank Considering Blockchain Implementation In Banks


Technical Analysis
GBP/JPY Trade idea
FxWirePro: Expect EUR/GBP interim justifiable corrections after jump above 61.8% fibos - stay short via tunnels for targets of 20-25 pips
FxWirePro:GBP/JPY faces strong resistance at 154.80, good to buy at dips
FxWirePro: BTC/USD consolidates in narrow range, good to buy at dips
FxWirePro: AUD/USD whipsaws on DMAs, leading oscillators noise with overbought pressures and selling momentum, bear trend to resume


Technology
New relaxed drone regulations will help the industry take off
Will the Tesla Model 3 recharge the U.S. electric vehicle market?
How drones can improve scientific research in the field
Coming to terms with digital grief: hashtags and emojis are here to stay
Networks of boosters could transform mobile phone signal in rural blackspots


Business
Event To Highlight Successes, Challenges Of Transforming Delivery Of Care For Underserved
Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology
Budget Car Rental Launches New Advertising Campaign Featuring Jessica Simpson
General Cannabis Announces Re-Launch of GC Supply
RedHill Biopharma Initiates Phase II Study of BEKINDA™ for Irritable Bowel Syndrome


Law
Twenty years after the High Court's Wik decision, how does the 'judicial activism' charge stand up?
What will the scrapping of Queensland's anti-bikie laws mean for organised crime?
Should alcohol limits for men and women really be the same?
ICC's Bemba ruling is a landmark, but falls short of a big leap
How the death penalty may keep innocent people in prison


Health
Health Check: does sex count as exercise?
There are no 'schizophrenia genes': here's why
Booze and driving don't mix but a zero blood alcohol limit isn't the answer
Medical tourism: having an op overseas adds to the everyday risk of surgery
The backlash against fish oil has been overcooked – here's why




Contributors



EconoTimes Series



worrisome-signs-series
Worrisome Signs Series


fx-currency-hedging-strategy-series
FX Hedging Strategy Series


bitcoin-digital-currency-revolution-series
Digital Currency Revolution


us-election-series
US Election Series


electric-car-series
Electric Car Series


AlphaPulse


Opinions


Adrian Beaumont


Adrian Beaumont

Cruz sweeps all 34 Colorado delegates, making contested Republican convention more likely


Chris McCarthy


Chris McCarthy

Robots can help young patients engage in rehab


Elizabeth Webster


Elizabeth Webster

To embrace our future as an innovation nation, we'll need to learn from the past


Miranda Stewart


Miranda Stewart

Five ideas to help fix Australia's tax system







Quotes by TradingView






Most Popular


1.


Industry Leaders Discuss Blockchain Technology’s Limitless Potential At COALA Blockchain Workshop NYC




2.


Storj Labs Joins Microsoft's Azure Blockchain as a Service Platform




3.


Big Banks To Attend European Blockchain Congress On April 27




4.


Russian Central Bank Considering Blockchain Implementation In Banks




5.


Cryptocurrency Wallet Service CoinWallet Announces Closure Following Data Breach


6.


FxWirePro: Nikkei225 faces strong resistance at 16050, good to sell on rallies




7.


Why teachers are unable to stop bias-based bullying




8.


Gold breaks major resistance at $1245, jump till $1260/$1271 is possible